Keywords: novartis, glivec, gains, fda, ok, first-line, treatment
Novartis' Glivec gains FDA OK for first-line treatment
Article | 06 January 2003
Swiss drug major Novartis announces that the US Food and DrugAdministration has approved Gleevec/Glivec (imatinib mesylate) for first-line treatment ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
